These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 29070883)

  • 1. Combined immunotherapy with anti-PDL-1/PD-1 and anti-CD4 antibodies cures syngeneic disseminated neuroblastoma.
    Rigo V; Emionite L; Daga A; Astigiano S; Corrias MV; Quintarelli C; Locatelli F; Ferrini S; Croce M
    Sci Rep; 2017 Oct; 7(1):14049. PubMed ID: 29070883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transient depletion of CD4(+) T cells augments IL-21-based immunotherapy of disseminated neuroblastoma in syngeneic mice.
    Croce M; Corrias MV; Orengo AM; Brizzolara A; Carlini B; Borghi M; Rigo V; Pistoia V; Ferrini S
    Int J Cancer; 2010 Sep; 127(5):1141-50. PubMed ID: 20039320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant IL-21 and anti-CD4 antibodies cooperate in syngeneic neuroblastoma immunotherapy and mediate long-lasting immunity.
    Rigo V; Corrias MV; Orengo AM; Brizzolara A; Emionite L; Fenoglio D; Filaci G; Croce M; Ferrini S
    Cancer Immunol Immunother; 2014 May; 63(5):501-11. PubMed ID: 24647609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Robust Antitumor Effects of Combined Anti-CD4-Depleting Antibody and Anti-PD-1/PD-L1 Immune Checkpoint Antibody Treatment in Mice.
    Ueha S; Yokochi S; Ishiwata Y; Ogiwara H; Chand K; Nakajima T; Hachiga K; Shichino S; Terashima Y; Toda E; Shand FH; Kakimi K; Ito S; Matsushima K
    Cancer Immunol Res; 2015 Jun; 3(6):631-40. PubMed ID: 25711759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade.
    Li HY; McSharry M; Bullock B; Nguyen TT; Kwak J; Poczobutt JM; Sippel TR; Heasley LE; Weiser-Evans MC; Clambey ET; Nemenoff RA
    Cancer Immunol Res; 2017 Sep; 5(9):767-777. PubMed ID: 28819064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carboplatin and programmed death-ligand 1 blockade synergistically produce a similar antitumor effect to carboplatin alone in murine ID8 ovarian cancer model.
    Zhu X; Xu J; Cai H; Lang J
    J Obstet Gynaecol Res; 2018 Feb; 44(2):303-311. PubMed ID: 29171115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
    Guo Z; Wang H; Meng F; Li J; Zhang S
    J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma.
    Rataj F; Kraus FBT; Chaloupka M; Grassmann S; Heise C; Cadilha BL; Duewell P; Endres S; Kobold S
    Front Immunol; 2018; 9():1955. PubMed ID: 30214445
    [No Abstract]   [Full Text] [Related]  

  • 9. Immune Checkpoint Inhibition Followed by Tumor Infiltration of Dendritic Cells in Murine Neuro-2a Neuroblastoma.
    Inoue S; Horiuchi Y; Setoyama Y; Takeuchi Y; Beck Y; Murakami T; Odaka A
    J Surg Res; 2020 Sep; 253():201-213. PubMed ID: 32380346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of regulatory T cells and checkpoint inhibition in hepatocellular carcinoma.
    Langhans B; Nischalke HD; Krämer B; Dold L; Lutz P; Mohr R; Vogt A; Toma M; Eis-Hübinger AM; Nattermann J; Strassburg CP; Gonzalez-Carmona MA; Spengler U
    Cancer Immunol Immunother; 2019 Dec; 68(12):2055-2066. PubMed ID: 31724091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human CD8
    Machicote A; Belén S; Baz P; Billordo LA; Fainboim L
    Front Immunol; 2018; 9():2788. PubMed ID: 30555473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T cell mediated immunity after combination therapy with intralesional PV-10 and blockade of the PD-1/PD-L1 pathway in a murine melanoma model.
    Liu H; Weber A; Morse J; Kodumudi K; Scott E; Mullinax J; Sarnaik AA; Pilon-Thomas S
    PLoS One; 2018; 13(4):e0196033. PubMed ID: 29694419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined Inhibition of TGF-β Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models.
    Sow HS; Ren J; Camps M; Ossendorp F; Ten Dijke P
    Cells; 2019 Apr; 8(4):. PubMed ID: 30959852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-L1-expressing natural killer cells predict favorable prognosis and response to PD-1/PD-L1 blockade in neuroblastoma.
    Song M; Huang Y; Hong Y; Liu J; Zhu J; Lu S; Wang J; Sun F; Huang J; Xu J; Tang Y; Xia JC; Zhang Y
    Oncoimmunology; 2024; 13(1):2289738. PubMed ID: 38125723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced Tumor Control with Combination mTOR and PD-L1 Inhibition in Syngeneic Oral Cavity Cancers.
    Moore EC; Cash HA; Caruso AM; Uppaluri R; Hodge JW; Van Waes C; Allen CT
    Cancer Immunol Res; 2016 Jul; 4(7):611-20. PubMed ID: 27076449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti-PD-1 and Anti-CD137 Monoclonal Antibodies.
    Azpilikueta A; Agorreta J; Labiano S; Pérez-Gracia JL; Sánchez-Paulete AR; Aznar MA; Ajona D; Gil-Bazo I; Larrayoz M; Teijeira A; Rodriguez-Ruiz ME; Pio R; Montuenga LM; Melero I
    J Thorac Oncol; 2016 Apr; 11(4):524-36. PubMed ID: 26845193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD25+ regulatory T cell inhibition enhances vaccine-induced immunity to neuroblastoma.
    Johnson BD; Jing W; Orentas RJ
    J Immunother; 2007; 30(2):203-14. PubMed ID: 17471167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The PD-L1/4-1BB Bispecific Antibody-Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner.
    Peper-Gabriel JK; Pavlidou M; Pattarini L; Morales-Kastresana A; Jaquin TJ; Gallou C; Hansbauer EM; Richter M; Lelievre H; Scholer-Dahirel A; Bossenmaier B; Sancerne C; Riviere M; Grandclaudon M; Zettl M; Bel Aiba RS; Rothe C; Blanc V; Olwill SA
    Clin Cancer Res; 2022 Aug; 28(15):3387-3399. PubMed ID: 35121624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer.
    Schofield DJ; Percival-Alwyn J; Rytelewski M; Hood J; Rothstein R; Wetzel L; McGlinchey K; Adjei G; Watkins A; Machiesky L; Chen W; Andrews J; Groves M; Morrow M; Stewart RA; Leinster A; Wilkinson RW; Hammond SA; Luheshi N; Dobson C; Oberst M
    MAbs; 2021; 13(1):1857100. PubMed ID: 33397194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.